Related Experiment Video
Updated: May 30, 2025

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
Efficacy of double filtration plasmapheresis in hyperlipidemia acute pancreatitis: a retrospective observational
Rong Qin1,2, Yibei Liu1,2, Rui Ding1,2
1Department of Gastroenterology, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, 650051, China.
Background:
This study examines the role and effectiveness of double filtration plasmapheresis (DFPP) in managing hyperlipidemiclipidemic acute pancreatitis (HLAP).
Methods:
Comparative analysis was conducted between two groups: one treated with DFPP and one without. Comparative parameters included blood lipid levels, inflammatory factors, vital signs, disease severity scores, and complication rates.
Results:
A total of 97 HLAP patients were included in the study. Within-group analysis revealed significant pre- and post-treatment changes in total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), white blood cell count (WBC), neutrophil percentage (N%), systemic immune-inflammation index (SII), mean arterial pressure (MAP), bedside index for severity in acute pancreatitis (BISAP), and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores in the DFPP group (P < 0.05). In contrast, the without DFPP group showed significant changes in TC, TG, LDL-C, WBC, N%, SII, systemic inflammation response index (SIRI), panimmune-inflammation value (PIV), respiration rate (RR), and APACHE II scores (P < 0.05). Significant differences in TC, TG, HDL-C, LDL-C, and RR were found between the DFPP and without DFPP groups (P < 0.05). The DFPP group exhibited greater reductions in TG levels and more individual variability. In terms of complications, the rate of systemic inflammatory response syndrome (SIRS) differed significantly between the groups (P < 0.05).
Conclusions:
DFPP can significantly improve short-term outcomes, reduce lipid levels, and reduce the incidence of complications such as SIRS in HLAP patients compared with those not receiving DFPP treatment. The clinical utility of DFPP is considerable, and further exploration and implementation of this method are warranted.
More Related Videos
07:38Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include: